Touch and Emotion in Haptic and Product Design

The emotional experience of products can have enormous impact on the overall product experience: someone who is feeling positive is more likely to be accepting of novel products or to be more tolerant of unexpected or unusual interface behaviours. Being able to improve users’ emotions through product interaction has clear benefits and is currently the focus of designers all over the world. The extent to which touch-based information can affect a user’s experience and observable behaviour has been given relatively little attention in haptic technology or other touch-based products where research has tended to focus on psychophysics relating to technical development, in the case of the former, and usability in the case of the latter. The objective of this research was therefore to begin to explore generalizable and useful relationship(s) between design parameters specific to the sense of touch and the emotional response to tactile experiences. To this end, a theoretical ’touch-emotion model’ was developed that incorporates stages from existing information and emotion processing models, and a subset of pathways (the ‘Affective’, ‘Cognitive’, and ‘Behaviour Pathways’) was explored. Four experiments were performed to examine how changes in various touch factors, such as surface roughness and availability of haptic (that is, touch-based) information during exploration, impacted user emotional experience and behaviour in the context of the model’s framework. These experiments also manipulated factors related to the experience of touch in real-world situations, such as the availability of visual information and product context. Exploration of the different pathways of the touch-emotion model guided the analysis of the experiments. In exploring the Affective Pathway, a robust relationship was found between increasing roughness and decreasing emotional valence (n = 36, p < 0.005), regardless of the availability of haptic or visual information. This finding expands earlier research that focused on the effect of tactile stimuli on user preference. The impact of texture on the Cognitive Pathway was examined by priming participants to think of the stimuli as objects varying in emotional commitment, such as a common mug (lower) or a personal cell phone (higher). Emotional response again decreased as roughness increased, regardless of primed context (n = 27, p < 0.002) and the primed contexts marginally appeared to generally improve or reduce emotional response (n = 27, p < 0.08). Finally, the exploration of the Behaviour Pathway considered the ability of roughness-evoked emotion to act as a mediator between physical stimuli and observable behaviour, revealing that, contrary to the hypothesis that increased emotional valence would increase time spent reflecting on the stimuli, increased emotion magnitude (regardless of the positive or negative valence of the emotion) was associated with increased time spent in reflection (n = 33, p < 0.002). Results relating to the Behaviour Pathway suggested that the portion of the touch-emotion model that included the last stages of information processing, observable behaviour, may need to be revised. However, the insights of the Affective and Cognitive Pathway analyses are consistent with the information processing stages within those pathways and give support to the related portions of the touch-emotion model. The analysis of demographics data collected from all four experiments also revealed interesting findings which are anticipated to have application in customizing haptic technology for individual users. For example, correlations were found between self-reported tactual importance (measured with a questionnaire) and age (n = 79, r = 0.28, p < 0.03) and between self-reported tactual importance and sensitivity to increased roughness (n = 79, r = -0.27, p < 0.04). Higher response times were also observed with increased age (rIT = 0.49, rRT = 0.48; p < 0.01). This research contributes to the understanding of how emotion and emotionevoked behaviour may be impacted by changing touch factors using the exemplar of roughness as the touch factor of interest, experienced multimodally and in varying situations. If a design goal is to contribute to user emotional experience of a product, then the findings of this work have the potential to impact design decisions relating to surface texture components of hand-held products as well as for virtual surface textures generated by haptic technology. Further, the touchemotion model may provide a guide for the systematic exploration of the relationships between surface texture, cognitive processing, and emotional response

Cataloging Coding Sequence Variations in Human Genome Databases

BACKGROUND: With the recent growth of information on sequence variations in the human genome, predictions regarding the functional effects and relevance to disease phenotypes of coding sequence variations are becoming increasingly important. The aims of this study were to catalog protein-coding sequence variations (CVs) occurring in genetic variation databases and to use bioinformatic programs to analyze CVs. In addition, we aim to provide insight into the functionality of the reference databases. METHODOLOGY AND FINDINGS: To catalog CVs on a genome-wide scale with regard to protein function and disease, we investigated three representative databases; the Human Gene Mutation Database (HGMD), the Single Nucleotide Polymorphisms database (dbSNP), and the Haplotype Map (HapMap). Using these three databases, we analyzed CVs at the protein function level with bioinformatic programs. We proposed a combinatorial approach using the Support Vector Machine (SVM) to increase the performance of the prediction programs. By cataloging the coding sequence variations using these databases, we found that 4.36% of CVs from HGMD are concurrently registered in dbSNP (8.11% of CVs from dbSNP are concurrent in HGMD). The pattern of substitutions and functional consequences predicted by three bioinformatic programs was significantly different among concurrent CVs, and CVs occurring solely in HGMD or in dbSNP. The experimental results showed that the proposed SVM combination noticeably outperformed the individual prediction programs. CONCLUSIONS: This is the first study to compare human sequence variations in HGMD, dbSNP and HapMap at the genome-wide level. We found that a significant proportion of CVs in HGMD and dbSNP overlap, and we emphasize the need to use caution when interpreting the phenotypic relevance of these concurrent CVs. Combining bioinformatic programs can be helpful in predicting the functional consequences of CVs because it improved the performance of functional predictions

Genetics of immunoglobulin-A vasculitis (Henoch-Schönlein purpura): An updated review

Immunoglobulin-A vasculitis (IgAV) is classically a childhood small-sized blood vessel vasculitis with predominant involvement of the skin. Gastrointestinal and joint manifestations are common in patients diagnosed with this condition. Nephritis, which is more severe in adults, constitutes the most feared complication of this vasculitis. The molecular bases underlying the origin of IgAV have not been completely elucidated. Nevertheless, several pieces of evidence support the claim that genes play a crucial role in the pathogenesis of this disease. The human leukocyte antigen (HLA) region is, until now, the main genetic factor associated with IgAV pathogenesis. Besides a strong association with HLA class II alleles, specifically HLA-DRB1 alleles, HLA class I alleles also seem to influence on the predisposition of this disease. Other gene polymorphisms located outside the HLA region, including those coding cytokines, chemokines, adhesion molecules as well as those related to T-cells, aberrant glycosylation of IgA1, nitric oxide production, neoangiogenesis, renin-angiotensin system and lipid, Pyrin and homocysteine metabolism, may be implicated not only in the predisposition to IgAV but also in its severity. An update of the current knowledge of the genetic component associated with the pathogenesis of IgAV is detailed in this review.Acknowledgements: RL-Mis supported by the Miguel Servet I programme of the Spanish Ministry of Economy and Competitiveness through the grant CP16/ 00033. FG is recipient of a Sara Borrell postdoctoral fellowship from the “Instituto Carlos III de Salud” at the Spanish Ministry of Health (Spain) (CD15/00095). SR-M is supported by funds from the RETICS Program (RIER) (RD16/0012/0009). FDC is supported by the Ramón y Cajal programme of the Spanish Ministry of Economy and Competitiveness through the grant RYC-2014-16458

Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment

Variation in the human genome is a most important cause of variable response to drugs and other xenobiotics. Susceptibility to almost all diseases is determined to some extent by genetic variation. Driven by the advances in molecular biology, pharmacogenetics has evolved within the past 40 years from a niche discipline to a major driving force of clinical pharmacology, and it is currently one of the most actively pursued disciplines in applied biomedical research in general. Nowadays we can assess more than 1,000,000 polymorphisms or the expression of more than 25,000 genes in each participant of a clinical study – at affordable costs. This has not yet significantly changed common therapeutic practices, but a number of physicians are starting to consider polymorphisms, such as those in CYP2C9, CYP2C19, CYP2D6, TPMT and VKORC1, in daily medical practice. More obviously, pharmacogenetics has changed the practices and requirements in preclinical and clinical drug research; large clinical trials without a pharmacogenomic add-on appear to have become the minority. This review is about how the discipline of pharmacogenetics has evolved from the analysis of single proteins to current approaches involving the broad analyses of the entire genome and of all mRNA species or all metabolites and other approaches aimed at trying to understand the entire biological system. Pharmacogenetics and genomics are becoming substantially integrated fields of the profession of clinical pharmacology, and education in the relevant methods, knowledge and concepts form an indispensable part of the clinical pharmacology curriculum and the professional life of pharmacologists from early drug discovery to pharmacovigilance

Measurement of the cross-section for b-jets produced in association with a Z boson at root s=7 TeV with the ATLAS detector ATLAS Collaboration

A measurement is presented of the inclusive cross-section for b-jet production in association with a Z boson in pp collisions at a centre-of-mass energy of root s = 7 TeV. The analysis uses the data sample collected by the ATLAS experiment in 2010, corresponding to an integrated luminosity of approximately 36 pb(-1). The event selection requires a Z boson decaying into high P-T electrons or muons, and at least one b-jet, identified by its displaced vertex, with transverse momentum p(T) > 25 GeV and rapidity vertical bar y vertical bar < 2.1. After subtraction of background processes, the yield is extracted from the vertex mass distribution of the candidate b-jets. The ratio of this cross-section to the inclusive Z cross-section (the average number of b-jets per Z event) is also measured. Both results are found to be in good agreement with perturbative QCD predictions at next-to-leading order